Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Hengrui Medicine is a leading pharmaceutical company based in China with a focus on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products. Hengrui was established in 1970 and listed in Shanghai Stock Exchange in 2000. The company ranks top 30 worldwide in pharmaceuticals industry by a market capitalization of over 50 billion USD, and has more than 25,000 employees worldwide. Hengrui not only stands out as a front-runner in cancer drugs, contrast agents, and surgical medicines, but is also a lead member of the National Anti-Tumor Medicine Technology Innovation Industry-Education-Research Alliance. Hengrui owns a National Targeted Drug Engineering Technology Research Center, and a post-doctoral research station. In May 2018, Hengrui Medicine was listed in Forbes’s top 100 world’s most innovative companies and ranked the 64th, where only 7 companies from China were on the list.